Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
Koji Haratani(Dana-Farber Cancer Institute), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Yasutaka Chiba(Kindai University Hospital), Kazuko Sakai(Kindai University Sakai Hospital), Yosuke Togashi(Okayama University), Hiroshige Yoshioka(Harbin Medical University), Hidetoshi Hayashi(Kindai University), Kimio Yonesaka(Kindai University), Taro Tanaka(Kurashiki Central Hospital), Kazuya Tanimura(Kishiwada City Hospital), Shuta Tomida(Okayama University), Kenya Hayashi(Nagasaki University), Takayuki Takahama(Kindai University), Junko Tanizaki(Kindai University Sakai Hospital), Tetsuya Mitsudomi(Kindai University), Hiroyasu Kaneda(Osaka City University), Masayuki Takeda(Kindai University), Takeshi Yoshida(Kanazawa University), Tadashi Ishida(Kurashiki Central Hospital), Yoshikane Nonagase(Kindai University), Kaoru Tanaka(Kindai University), Kazuto Nishio(Kindai University Sakai Hospital)
Cited by 294
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k